Krogerus advised Carnegie Investment Bank as lead manager and bookrunner on the EUR 30.7 million public offering of Faron Pharmaceuticals and on its preceding issuance of convertible capital loans in the total amount of EUR 3.2 million and a private placement of EUR 4.8 million.
Faron is a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies and its shares are listed on Nasdaq First North Growth Market Finland and as depositary interests on AIM in the United Kingdom.
The public offering was fully subscribed. The offering consisted of a public offering to private individuals and legal entities in Finland and an institutional offering to institutional investors internationally, and a separate open offer to qualifying holders of depositary interests in the United Kingdom and elsewhere as well as a retail offer to retail investors in the United Kingdom.
The Krogerus team was led by Partner Tom Fagernäs, and he was assisted by Senior Associates Samuli Torpisto and Olli Silvennoinen and Associates Manu Honkanen, Marika Nieminen and Peter Partanen.
Team
Latest references
View all referencesKrogerus advises Nordic Ren-Gas on a EUR 300 million investment in a renewable e-methane production facility
Krogerus advises Northern Horizon on 7 transactions with a total value of EUR 55 million
Krogerus advises Talliosake on the launch of Talli together with Heitman